Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies how well sunitinib malate or valproic acid works in
preventing high-risk uveal (eye) melanoma from spreading to other parts of the body.
Sunitinib malate may stop the transmission of growth signals into tumor cells and prevents
these cells from growing. Valproic acid may change the expression of some genes in uveal
melanoma and suppress tumor growth.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University